Healthpeak posts Q3 loss of $0.17 per share and cuts 2025 EPS guidance
Healthpeak reported a third-quarter 2025 net loss applicable to common shares of $117.3 million, or $0.17 per share, compared with net income of $85.7 million, or $0.12 per share, a year earlier. The loss reflects $175.8 million of impairment charges on unconsolidated joint ventures. The company cut its full-year 2025 diluted earnings per share guidance to $0.00 to $0.06 from $0.25 to $0.31, while reaffirming its Nareit FFO guidance of $1.78 to $1.84 per share.
Key points
- Third-quarter Nareit FFO rose to $0.45 per share from $0.44 a year earlier; FFO as Adjusted was $0.46 versus $0.45.
- Third-quarter net loss of $117.3 million ($0.17 per share) included $175.8 million of impairments on unconsolidated joint ventures.
- 2025 diluted EPS guidance lowered to $0.00 to $0.06 from $0.25 to $0.31; Nareit FFO guidance of $1.78 to $1.84 reaffirmed.
- Board declared monthly dividends of $0.10167 per share for October, November and December 2025, totaling $0.305 for the fourth quarter.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:12 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 23, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.